A $4 million Series B is fueling Meduloc LLC’s move from FDA clearance to controlled commercialization of its flexible intramedullary fracture-fixation platform.
Company News Premium
Meduloc Raises $4 Million in Series B
1 min read Premium comments

Medulocnitinol fixationfracture fixationAndre Ethiernickel titanium alloyGenHenn Capital
Author
React:
